These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 17890244

  • 1. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
    Montagnino G, Sandrini S, Iorio B, Schena FP, Carmellini M, Rigotti P, Cossu M, Altieri P, Salvadori M, Stefoni S, Corbetta G, Ponticelli C.
    Nephrol Dial Transplant; 2008 Feb; 23(2):707-14. PubMed ID: 17890244
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.
    Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C.
    Transplant Proc; 2005 Mar; 37(2):788-90. PubMed ID: 15848532
    [Abstract] [Full Text] [Related]

  • 3. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial.
    Salvadori M, Scolari MP, Bertoni E, Citterio F, Rigotti P, Cossu M, Dal Canton A, Tisone G, Albertazzi A, Pisani F, Gubbiotti G, Piredda G, Busnach G, Sparacino V, Goepel V, Messa P, Berloco P, Montanaro D, Veroux P, Federico S, Bartezaghi M, Corbetta G, Ponticelli C.
    Transplantation; 2009 Nov 27; 88(10):1194-202. PubMed ID: 19935373
    [Abstract] [Full Text] [Related]

  • 4. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 27; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 5. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
    Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM, Everolimus Pediatric Study Group.
    Pediatr Transplant; 2008 Jun 27; 12(4):456-63. PubMed ID: 18466433
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 7. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
    Gonzalez F, Espinoza M, Herrera P, Rocca X, Reynolds E, Lorca E, Roessler E, Hidalgo J, Espinoza O.
    Transplant Proc; 2010 Feb 27; 42(1):270-2. PubMed ID: 20172327
    [Abstract] [Full Text] [Related]

  • 8. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 9. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G, Pisani F, Iorio B, Lucchesi C, De Luca L, Ielpo B, D'Andria D, Tariciotti L, Tisone G.
    Transplant Proc; 2006 May 15; 38(4):1018-9. PubMed ID: 16757249
    [Abstract] [Full Text] [Related]

  • 10. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 15; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 11. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep 15; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

  • 12. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 13. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 14. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 15. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 16. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group.
    Sinclair NR.
    CMAJ; 1992 Sep 01; 147(5):645-57. PubMed ID: 1521210
    [Abstract] [Full Text] [Related]

  • 17. [Withdrawal of prednisone from a triple combination of immunosuppressive agents after kidney transplantation].
    Matl I, Lácha J, Lodererová A, Símová M, Teplan V, Lánská V, Vítko S.
    Cas Lek Cesk; 2000 Mar 01; 139(4):115-9. PubMed ID: 10838741
    [Abstract] [Full Text] [Related]

  • 18. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
    Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study Group.
    Ann Surg; 2008 Oct 01; 248(4):564-77. PubMed ID: 18936569
    [Abstract] [Full Text] [Related]

  • 19. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan 01; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 20. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M, Wasler A, Prenner G, Stiegler P, Stadlbauer V, Schwarz M, Tscheliessnigg K.
    Transpl Immunol; 2006 Jun 01; 16(1):46-51. PubMed ID: 16701176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.